Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation.
暂无分享,去创建一个
C. Robic | P. Bruneval | C. Corot | J. Idee | C. Factor | B. Bonnemain | J. Schroeder | N. Fretellier | Jean-François Mayer | F. Delaloge | M. Salhi | H. Siegmund | Thibaut Chevalier | Gaëlle Jestin-Mayer | J. Fabicki
[1] Sarfaraz Niazi,et al. Impurities in New Drug Products , 2016 .
[2] C. Robic,et al. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update , 2014, Critical reviews in toxicology.
[3] J. Heverhagen,et al. Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis , 2014, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.
[4] S. Jimenez,et al. Induction of a type I interferon signature in normal human monocytes by gadolinium‐based contrast agents: comparison of linear and macrocyclic agents , 2014, Clinical and experimental immunology.
[5] M. Port,et al. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[6] V. Runge,et al. MRI contrast agents: Basic chemistry and safety , 2012, Journal of magnetic resonance imaging : JMRI.
[7] B. Wagner,et al. Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. , 2012, Radiology.
[8] M. Port,et al. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide , 2012, British journal of pharmacology.
[9] M. Rehman,et al. Stimulation of Fibroblast Proliferation by Insoluble Gadolinium Salts , 2011, Biological Trace Element Research.
[10] Arthur E. Martell,et al. Critical Stability Constants , 2011 .
[11] A. Abu-Alfa,et al. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. , 2011, Advances in chronic kidney disease.
[12] M. Port,et al. Comparative In Vivo Dissociation of Gadolinium Chelates in Renally Impaired Rats: A Relaxometry Study , 2011, Investigative radiology.
[13] J. Varani,et al. Fibroblast Response to Lanthanoid Metal Ion Stimulation: Potential Contribution to Fibrotic Tissue Injury , 2011, Biological Trace Element Research.
[14] S. Morcos. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? , 2011, European Radiology.
[15] J. Varani,et al. Fibroblast Response to Gadolinium: Role for Platelet-Derived Growth Factor Receptor , 2010, Investigative radiology.
[16] C. Anderson,et al. The biodistribution of [153Gd]Gd‐labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice , 2010, Magnetic resonance in medicine.
[17] Kui Wang,et al. Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells , 2010, JBIC Journal of Biological Inorganic Chemistry.
[18] C. Robic,et al. Role of thermodynamic and kinetic parameters in gadolinium chelate stability , 2009, Journal of magnetic resonance imaging : JMRI.
[19] T. Steger-Hartmann,et al. Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.
[20] D. Løvhaug,et al. Effects of gadolinium contrast agents in naïve and nephrectomized rats: Relevance to nephrogenic systemic fibrosis , 2009, Acta radiologica.
[21] R. Swartz,et al. Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts , 2009, Investigative radiology.
[22] M. Mack,et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[23] T. Frenzel,et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.
[24] Hanns-Joachim Weinmann,et al. Gadolinium‐based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand , 2008, Journal of magnetic resonance imaging : JMRI.
[25] C. Robic,et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.
[26] T. Frenzel,et al. A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.
[27] L. Skov,et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long‐term persistence in nephrogenic systemic fibrosis , 2007, The British journal of dermatology.
[28] A. Morisetti,et al. Toxicological assessment of gadolinium release from contrast media. , 2007, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[29] S. Morcos. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.
[30] Lone Skov,et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.
[31] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[32] Dawn G Goodman,et al. Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.
[33] S. Curley,et al. Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases , 1992, Clinical & Experimental Metastasis.
[34] P. Bell,et al. The effect of kupffer cell stimulation or depression on the development of liver metastases in the rat , 2004, Cancer Immunology, Immunotherapy.
[35] L. Gustafsson,et al. Basic experimental studies and clinical aspects of gadolinium salts and chelates. , 2006, Cardiovascular drug reviews.
[36] A. Pałasz,et al. Toxicological and cytophysiological aspects of lanthanides action. , 2000, Acta biochimica Polonica.
[37] A. Reid,et al. Gadolinium Chloride Toxicity in the Rat , 1997, Toxicologic pathology.
[38] T. Monticello,et al. Utilization of Electron Probe Microanalysis in Gadolinium-Treated Mice , 1996, Toxicologic pathology.
[39] S. Arii,et al. The role of Kupffer cells in the surveillance of tumor growth in the liver. , 1993, The Journal of surgical research.
[40] P. Wedeking,et al. Dose-dependent biodistribution of [153Gd]Gd(acetate)n in mice. , 1993, Nuclear medicine and biology.
[41] M. W. Flye,et al. Kupffer cell blockade increases mortality during intra-abdominal sepsis despite improving systemic immunity. , 1990, Archives of surgery.
[42] Analysis of Repeated-Measures Designs , 1989 .
[43] E. Smith. Analysis of repeated measures designs. , 1987, The Journal of pediatrics.